Franziskus Hospital Harderberg — Clinical Trial Site

47 Registered trials

20 Currently recruiting

Organisation

Franziskus Hospital Harderberg

Location

Georgsmarienhuette, Germany

Identifier

ORG-100033567

Address

Alte Rothenfelder Strasse 23, Harderberg, 49124, Germany

Departments

-
2602: Internistische Onkologie und Hämatologie
Abteilung für Senologie
Apotheke
Center for Hematology and Oncology
Klinik fuer Thoraxonkologie
Klinik für Thoraxonkologie
Medical oncology
Medizinisches Versorgungszentrum II der Niels Stensen Kliniken
MVZ I der Niels-Stensen-Kliniken Zentrum für Internistische Onkologie und Hämatologie
MVZ II der Niels Stensen Kliniken
MVZ II der Niels Stensen Kliniken - Onkologie u. Hämatologie
MVZ II der Niels Stensen Kliniken - Sektion Thoraxonkologie
MVZ II der Niels-Stensen-Kliniken Zentrum für Internistische Onkologie und Hämatologie
MVZ II Zentrum für Hämatologie und Onkologie, Sektion Thoraxonkologie
MVZ II, Sektion Thoraxonkologie
N/A
Niels-Stensen-Kliniken
Oncology
Oncology and Hematology
Onkologie und Haematologie
Onkologie/Hämatologie
Sektion Thoraxonkologie
Thoracic Oncology
Thoraxonkologie
Zentrum fuer Haematologie und Onkologie
Zentrum fuer Internistische Onkologie und Haematologie
Zentrum für internistische Hämatologie und Onkologie
Zentrum für Internistische Onkologie und Hämatologie der Niels-Stensen-Kliniken"
Zentrum für Internistische Onkologie und Haematologie
Zentrum für Internistische Onkologie und Hämatologie
Zentrum für Onkologie und Hämatologie MVZ II

Clinical trials at this site (47)

Search interface

A trial to learn how well Dato-DXd and rilvegostomig work and how safe they are in participants with stage I adenocarcinoma non-small cell l… Pending

2024-512195-35-00 Stage I adenocarcinoma non-small cell lung cancer (NSCL 5
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or… Pending

2025-523461-17-01 LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANC 5
Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/… Recruiting

2025-522484-15-00 ER+/HER2- early breast cancer 5 2026-04-27
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib plus Ribociclib plus Fulvestrant Versus Placebo plus Ribociclib plus Fulve… Recruiting

2025-523013-28-00 Endocrine-Resistant Hormone-Receptor-Positive, HER2-Neg 4 2026-04-07
ROSETTA Breast-01: The effects and safety of pumitamig in patients with triple-negative breast cancer Recruiting

2025-521884-12-00 First line triple-negative breast cancer (TNBC) 5 2026-03-19
Osimertinib plus chemotherapy as 1st line therapy in stage IV NSCLC patients with atypical EGFR mutations (AIO-TRK/YMO-0324) Recruiting

2024-516790-78-00 stage IV NSCLC (non-small-cell lung cancer) 4 2025-09-04
A randomized phase 3, double-blind, placebo-controlled study of elacestrant plus everolimus versus elacestrant in patients with estrogen rec… Recruiting

2024-512926-27-00 patients with estrogen receptor-positive/human epiderma 5 2024-12-12
Clinical trial that compares MK-2870 with or without pembrolizumab to chemotherapy in people with breast cancer that cannot be surgically re… Recruiting

2023-504918-29-00 Hormone receptor positive breast cancer 5 2024-08-22
A Phase 3, Open-Label, Randomized, Multi-Center Study of DZD9008 versus Platinum-Based Doublet Chemotherapy as First-Line Treatment for Pati… Recruiting

2022-502959-54-00 Locally Advanced or Metastatic Non-Small Cell Lung Canc 5 2023-09-26
A trial to learn how safe Dato-DXd is and how well it works in people with NSCLC that has advanced after receiving osimertinib Recruiting

2024-511362-37-00 Non squamous non-small cell lung cancer (NSCLC) 5 2026-02-18
Phase 3, Multicenter, Randomized, Open-label Clinical Study of GSK5764227, a B7-H3 Antibody Drug Conjugate (ADC), compared with Topotecan in… Recruiting

2025-521627-78-00 Neoplasms, Lung 5 2026-01-28
An open-label randomised, phase II trial of Datopotamab deruxtecan plus Durvalumab versus Datopotamab deruxtecan in patients with PDL1-negat… Recruiting

2024-519913-76-00 PDL1-negative metastatic triple-negative breast cancer 4 2025-12-09
Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Smal… Recruiting

2024-512302-25-00 Resected or Unresectable KRAS G12C-mutant Non-Small Cel 5 2025-06-06
A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad… Recruiting

2023-505077-32-00 Locally-advanced or metastatic non-squamous non-small c 5 2025-01-28
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting

2024-512279-10-00 Triple Negative Breast Cancer 5 2024-11-25
NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br… Recruiting

2023-508787-29-00 Triple-negative early breast cancer with low risk for r 4 2024-10-10
Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting

2023-504962-52-00 Triple negative breast cancer. 5 2024-07-10
An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) Recruiting

2023-504031-41-00 ER+/HER2- Early Breast Cancer 5 2024-03-25
Discontinuation of CDK4/6 inhibitors in patients with metastatic HR positive, HER2 negative breast cancer with durable disease control: A ra… Recruiting

2023-504141-31-00 Metastatic HR positive, HER2 negative breast cancer 4 2024-01-17
A multicentre, randomized trial in adults with de novo Philadelphia-Chromosome positive acute lymphoblastic leukemia to assess the efficacy … Recruiting

2024-517966-40-00 Acute lymphoblastic leukemia (ALL), de novo, Ph/BCR::AB 4 2023-07-13
CAPTOR-BC: COMPREHENSIVE ANALYSIS OF SPATIAL, TEMPORAL AND MOLECULAR PATTERNS OF RIBOCICLIB EFFICACY AND RESISTANCE IN ADVANCED BREAST CANCE… Recruiting

2022-500764-35-00 Patients with advanced HER2-negative, hormone receptor 6 2022-10-13
Post-resection/ ablation chemotherapy in patients with metastatic colorectal cancer (FIRE-9 - PORT / AIO-KRK-0418). Prospective, randomized,… Recruiting

2024-512174-10-00 metastatic colorectal cancer 5 2021-11-11
Phase III Trial of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed vs. Investigator’s Choice of the Standard of Care … Ended

2023-503231-17-00 Unresectable Pleural Mesothelioma 5 2024-04-26
NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel+carboplatin+trastuzumab+… Ended

2024-514458-61-01 HER2+ early breast cancer 4 2024-02-05